Myfortic (Mycophenolic Acid)

Mycophenolic acid, the active ingredient in Myfortic, is an antimetabolite presented as an oral tablet for oral use. It is employed to reduce the risk of organ rejection in transplant recipients, particularly those receiving a kidney graft. GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Myfortic is an antimetabolite immunosuppressant used in solid‑organ transplantation to inhibit lymphocyte proliferation. - Renal transplant: helps prevent graft rejection in kidney recipients. - Cardiac transplant: reduces the incidence of heart‑graft rejection. - Liver transplant: supports long‑term graft survival by suppressing immune response.

Myfortic may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: frequent loose stools. - Vomiting: occasional emesis. - Abdominal pain: cramping or discomfort. - Headache: transient mild headache. - Increased infection risk: higher susceptibility to common infections.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Anemia: decreased red blood cell count. - Severe infections: opportunistic or life‑threatening infections. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Malignancy: increased risk of certain cancers with long‑term use. - Gastrointestinal perforation: rare but serious bowel injury.

Patients receiving Myfortic should be monitored closely for safety and efficacy. - Blood counts: monitor complete blood count regularly to detect leukopenia or anemia. - Liver function: assess hepatic enzymes periodically. - Live vaccines: avoid administration while on therapy due to immunosuppression. - Renal function: adjust dosing in patients with impaired kidney function. - Infection signs: report fever, cough, or unusual symptoms promptly. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Myfortic can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: may reduce absorption of mycophenolic acid. - Cholestyramine or colestipol: can bind the drug and lower systemic exposure. - Cyclosporine or tacrolimus: may increase mycophenolic acid levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression; monitor blood counts closely. - Live attenuated vaccines: heightened infection risk; consider alternative immunizations.